PLEASANTON, Calif., June 3, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences:
The above presentations will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact:
Gunnar Hansen
Veeva Systems Inc.
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$215.95 |
Daily Change: | -4.71 -2.13 |
Daily Volume: | 1,165,694 |
Market Cap: | US$35.060B |
January 13, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load